View as an RSS Feed
View Steven Breazzano's Articles BY TICKER:
- Raptor Pharmaceuticals: Pipeline Worth a Closer Look
- Depomed's Recent Events Boost Balance Sheet
- DUSA Pharmaceuticals: Small-Cap Biotech With a Healthy Cash Flow
- The Patent Cliff: What Big Pharma Investors Need to Know
- Why Phase 3 Trials Fail: What Investors Need to Know
- Earnings Analysis: Ariad Pharmaceuticals
- What's Next for Protalix BioTherapeutics Shares Fall After FDA CRL?
- Prolor Biotech: Will Phase 2 Growth Hormone Results Bring Uptick?
- LPath, Inc.: Multiple Phase 2 Trials and Pfizer Partnership Provide Path to Profits
- iBio: Risky, But Early Stage Pipeline Potentially Offers Long-Term Reward
- Investors Feeling Pain of Depomed vs. Abbott
- Protalix BioTherapeutics: Recent Dip Represents Attractive Entry Point
- Near Term Catalysts for Ariad Pharma Add to Positive Outlook
- Ziopharm Oncology's Global Strategy Provides Potential Upside for Investors
- Depomed: Extended Release Pharmaceuticals and Extended Share Price Increases?
- Ariad Pharmaceuticals: Just the Beginning?
- Protalix BioTherapeutics: The Future of Recombinant Proteins?